Amedeo Smart

Free Medical Literature Service


 

Amedeo

Anemia

  Free Subscription

Articles published in
Nephron
    January 2021
  1. DUARTE I, Gameiro J, Outerelo C, Nogueira E, et al
    Atypical Hemolytic Uremic Syndrome and Nephrotic Syndrome Associated with Cytomegalovirus Infection.
    Nephron. 2021;145:188-191.
    >> Share

    August 2020
  2. WEN T, Zhang X, Wang Z, Zhou R, et al
    Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Patients with Renal Anemia: A Meta-Analysis of Randomized Trials.
    Nephron. 2020 Aug 31:1-11. doi: 10.1159/000508812.
    >> Share

    June 2020
  3. AKIZAWA T, Yamaguchi Y, Otsuka T, Reusch M, et al
    A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naive Chronic Kidney Disease Patients Not on Dialysis.
    Nephron. 2020 Jun 24:1-11. doi: 10.1159/000508100.
    >> Share

    January 2020
  4. ALFANDARY H, Rinat C, Gurevich E, Eisenstein I, et al
    Hemolytic Uremic Syndrome: A Contemporary Pediatric Experience.
    Nephron. 2020;144:109-117.
    >> Share

    August 2019
  5. AKIZAWA T, Macdougall IC, Berns JS, Yamamoto H, et al
    Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
    Nephron. 2019 Aug 6:1-12. doi: 10.1159/000502012.
    >> Share

    July 2018
  6. COZZOLINO M, Bolasco P, Ronco C, Conte G, et al
    Clinical Management of Chronic Kidney Disease Patients in Italy: Results from the IRIDE Study.
    Nephron. 2018 Jul 17:1-9. doi: 10.1159/000490769.
    >> Share

    June 2018
  7. FULLER DS, Robinson BM, Locatelli F, Pisoni RL, et al
    Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study.
    Nephron. 2018 Jun 26:1-7. doi: 10.1159/000490202.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016